A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3

PURPOSE: Non-surgical treatments for cervical intraepithelial neoplasia 2/3 (CIN2/3) are needed as surgical treatments have been shown to double preterm delivery rate. The goal of this study was to demonstrate safety of a human papillomavirus (HPV) therapeutic vaccine called PepCan, which consists o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Greenfield, William W, Stratton, Shawna L, Myrick, Rebecca S, Vaughn, Rita, Donnalley, Lisa M, Coleman, Hannah N, Mercado, Maria, Moerman-Herzog, Andrea M, Spencer, Horace J, Andrews-Collins, Nancy R, Hitt, Wilbur C, Low, Gordon M, Manning, Nirvana A, McKelvey, Samantha S, Smith, Dora, Smith, Michael V, Phillips, Amy M, Quick, C Matthew, Jeffus, Susanne K, Hutchins, Laura F, Nakagawa, Mayumi
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2015
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4590015/
https://ncbi.nlm.nih.gov/pubmed/26451301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1031439
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky